Commonwealth Equity Services
ANIX icon

Commonwealth Equity Services’s Anixa Biosciences ANIX Stock Holding History

Commonwealth Equity Services’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,571
Closed -$34K – 3831
2023
Q2 		$34K Buy
+10,571
New +$40.7K ﹤0.01% 3706

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Commonwealth Equity Services's ANIX Position: Q3 2023 in Review

Commonwealth Equity Services sold out of Anixa Biosciences (ANIX) in Q3 2023, closing a stake of 10,571 shares — an estimated $34K sold.

Commonwealth Equity Services first reported a position in ANIX in Q2 2023 and held it in 1 quarter. The position peaked at $34K in Q2 2023. 49 funds tracked by Wall St. Rank hold ANIX as of Q3 2023.

  • Commonwealth Equity Services reported no remaining Anixa Biosciences position as of Q3 2023 after selling out during the quarter.
  • Commonwealth Equity Services sold 10,571 Anixa Biosciences shares in Q3 2023, an estimated $34K.
  • Commonwealth Equity Services first reported a position in Anixa Biosciences in Q2 2023 and held it in 1 quarter.
  • Commonwealth Equity Services's Anixa Biosciences position peaked at $34K in Q2 2023.
  • 49 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2023.

Based on Commonwealth Equity Services's 13F filing for Q3 2023, filed 23 Oct 2023.